Screener
Tarsus Pharmaceuticals, Inc. TARS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $40,141 | $16,387 |
| Accrued payroll and benefits | 11,887 | 17,779 |
| Other accrued liabilities | 123,725 | 101,529 |
| Total current liabilities | 175,753 | 135,695 |
| Long-term debt, net | 72,762 | 72,438 |
| Other long-term liabilities | 15,895 | 10,599 |
| Total liabilities | 264,410 | 218,732 |
| Commitments and contingencies (Note 8) |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s total current liabilities?
- Tarsus Pharmaceuticals, Inc. (TARS) reported total current liabilities of $175.75M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s total current liabilities changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s total current liabilities increased by 94.7% year-over-year, from $90.25M to $175.75M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s total current liabilities has grown at a 90.7% compound annual growth rate (CAGR), from $5.39M to $135.7M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude